PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment
compared to healthy participants after a single oral dose of obicetrapib (10 mg).